Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients

Abstract This study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N = 302...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jira Chansaenroj, Ritthideach Yorsaeng, Nawarat Posuwan, Jiratchaya Puenpa, Nasamon Wanlapakorn, Natthinee Sudhinaraset, Manit Sripramote, Piti Chalongviriyalert, Supunee Jirajariyavej, Phatharaporn Kiatpanabhikul, Jatuporn Saiyarin, Chulikorn Soudon, Orawan Thienfaidee, Thitisan Palakawong Na Ayuthaya, Chantapat Brukesawan, Chintana Chirathaworn, Duangnapa Intharasongkroh, Dootchai Chaiwanichsiri, Mila Issarasongkhram, Rungrueng Kitphati, Anek Mungaomklang, Pijaya Nagavajara, Yong Poovorawan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/e60e4dbcc0c64a29898266a634977504
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e60e4dbcc0c64a29898266a634977504
record_format dspace
spelling oai:doaj.org-article:e60e4dbcc0c64a29898266a6349775042021-12-05T12:12:27ZLong-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients10.1038/s41598-021-02659-42045-2322https://doaj.org/article/e60e4dbcc0c64a29898266a6349775042021-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02659-4https://doaj.org/toc/2045-2322Abstract This study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N = 302) or multiple time points (N = 229) 3–12 months after COVID-19 symptom onset or SARS-CoV-2 detection in respiratory specimens was measured by semiquantitative chemiluminescent microparticle immunoassay. The 531 patients (966 specimens) were classified according to the presence or absence of pneumonia symptoms. Anti N IgG was detected in 87.5% of patients (328/375) at 3 months, 38.6% (93/241) at 6 months, 23.7% (49/207) at 9 months, and 26.6% (38/143) at 12 months. The anti-N IgG seropositivity rate was significantly lower at 6, 9, and 12 months than at 3 months (P < 0.01) and was higher in the pneumonia group than in the non-pneumonia/asymptomatic group at 6 months (P < 0.01), 9 months (P = 0.04), and 12 months (P = 0.04). The rate started to decline 6–12 months after symptom onset. Anti-N IgG sample/cutoff index was positively correlated with age (r = 0.192, P < 0.01) but negatively correlated with interval between symptom onset and blood sampling (r =  − 0.567, P < 0.01). These findings can guide vaccine strategies in recovered COVID-19 patients.Jira ChansaenrojRitthideach YorsaengNawarat PosuwanJiratchaya PuenpaNasamon WanlapakornNatthinee SudhinarasetManit SripramotePiti ChalongviriyalertSupunee JirajariyavejPhatharaporn KiatpanabhikulJatuporn SaiyarinChulikorn SoudonOrawan ThienfaideeThitisan Palakawong Na AyuthayaChantapat BrukesawanChintana ChirathawornDuangnapa IntharasongkrohDootchai ChaiwanichsiriMila IssarasongkhramRungrueng KitphatiAnek MungaomklangPijaya NagavajaraYong PoovorawanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Jira Chansaenroj
Ritthideach Yorsaeng
Nawarat Posuwan
Jiratchaya Puenpa
Nasamon Wanlapakorn
Natthinee Sudhinaraset
Manit Sripramote
Piti Chalongviriyalert
Supunee Jirajariyavej
Phatharaporn Kiatpanabhikul
Jatuporn Saiyarin
Chulikorn Soudon
Orawan Thienfaidee
Thitisan Palakawong Na Ayuthaya
Chantapat Brukesawan
Chintana Chirathaworn
Duangnapa Intharasongkroh
Dootchai Chaiwanichsiri
Mila Issarasongkhram
Rungrueng Kitphati
Anek Mungaomklang
Pijaya Nagavajara
Yong Poovorawan
Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients
description Abstract This study monitored the long-term immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in patients who had recovered from coronavirus disease (COVID)-19. Anti-nucleocapsid immunoglobulin G (anti-N IgG) titer in serum samples collected at a single (N = 302) or multiple time points (N = 229) 3–12 months after COVID-19 symptom onset or SARS-CoV-2 detection in respiratory specimens was measured by semiquantitative chemiluminescent microparticle immunoassay. The 531 patients (966 specimens) were classified according to the presence or absence of pneumonia symptoms. Anti N IgG was detected in 87.5% of patients (328/375) at 3 months, 38.6% (93/241) at 6 months, 23.7% (49/207) at 9 months, and 26.6% (38/143) at 12 months. The anti-N IgG seropositivity rate was significantly lower at 6, 9, and 12 months than at 3 months (P < 0.01) and was higher in the pneumonia group than in the non-pneumonia/asymptomatic group at 6 months (P < 0.01), 9 months (P = 0.04), and 12 months (P = 0.04). The rate started to decline 6–12 months after symptom onset. Anti-N IgG sample/cutoff index was positively correlated with age (r = 0.192, P < 0.01) but negatively correlated with interval between symptom onset and blood sampling (r =  − 0.567, P < 0.01). These findings can guide vaccine strategies in recovered COVID-19 patients.
format article
author Jira Chansaenroj
Ritthideach Yorsaeng
Nawarat Posuwan
Jiratchaya Puenpa
Nasamon Wanlapakorn
Natthinee Sudhinaraset
Manit Sripramote
Piti Chalongviriyalert
Supunee Jirajariyavej
Phatharaporn Kiatpanabhikul
Jatuporn Saiyarin
Chulikorn Soudon
Orawan Thienfaidee
Thitisan Palakawong Na Ayuthaya
Chantapat Brukesawan
Chintana Chirathaworn
Duangnapa Intharasongkroh
Dootchai Chaiwanichsiri
Mila Issarasongkhram
Rungrueng Kitphati
Anek Mungaomklang
Pijaya Nagavajara
Yong Poovorawan
author_facet Jira Chansaenroj
Ritthideach Yorsaeng
Nawarat Posuwan
Jiratchaya Puenpa
Nasamon Wanlapakorn
Natthinee Sudhinaraset
Manit Sripramote
Piti Chalongviriyalert
Supunee Jirajariyavej
Phatharaporn Kiatpanabhikul
Jatuporn Saiyarin
Chulikorn Soudon
Orawan Thienfaidee
Thitisan Palakawong Na Ayuthaya
Chantapat Brukesawan
Chintana Chirathaworn
Duangnapa Intharasongkroh
Dootchai Chaiwanichsiri
Mila Issarasongkhram
Rungrueng Kitphati
Anek Mungaomklang
Pijaya Nagavajara
Yong Poovorawan
author_sort Jira Chansaenroj
title Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients
title_short Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients
title_full Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients
title_fullStr Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients
title_full_unstemmed Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients
title_sort long-term specific igg response to sars-cov-2 nucleocapsid protein in recovered covid-19 patients
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/e60e4dbcc0c64a29898266a634977504
work_keys_str_mv AT jirachansaenroj longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT ritthideachyorsaeng longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT nawaratposuwan longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT jiratchayapuenpa longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT nasamonwanlapakorn longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT natthineesudhinaraset longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT manitsripramote longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT pitichalongviriyalert longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT supuneejirajariyavej longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT phatharapornkiatpanabhikul longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT jatupornsaiyarin longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT chulikornsoudon longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT orawanthienfaidee longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT thitisanpalakawongnaayuthaya longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT chantapatbrukesawan longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT chintanachirathaworn longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT duangnapaintharasongkroh longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT dootchaichaiwanichsiri longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT milaissarasongkhram longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT rungruengkitphati longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT anekmungaomklang longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT pijayanagavajara longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
AT yongpoovorawan longtermspecificiggresponsetosarscov2nucleocapsidproteininrecoveredcovid19patients
_version_ 1718372167258734592